ICSBP Is Essential for the Development of Mouse Type I Interferon-producing Cells and for the Generation and Activation of CD8α+ Dendritic Cells by Schiavoni, Giovanna et al.
 
The Journal of Experimental Medicine • Volume 196, Number 11, December 2, 2002 1415–1425
http://www.jem.org/cgi/doi/10.1084/jem.20021263
 
1415
 
ICSBP Is Essential for the Development of Mouse Type I 
Interferon-producing Cells and for the Generation and 
 
Activation of CD8
 
 
 
 
 
 Dendritic Cells
 
Giovanna Schiavoni,
 
1 
 
Fabrizio Mattei,
 
1 
 
Paola Sestili,
 
1
 
 Paola Borghi,
 
1
 
Massimo Venditti,
 
1 
 
Herbert C. Morse III,
 
2 
 
Filippo Belardelli,
 
1
 
 and Lucia Gabriele
 
1
 
1
 
Laboratory of Virology, Istituto Superiore di Sanità, 00161 Rome, Italy
 
2
 
Laboratory of Immunopathology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 
Bethesda, MD 20892
 
Abstract
 
Interferon (IFN) consensus sequence-binding protein (ICSBP) is a transcription factor playing a
critical role in the regulation of lineage commitment, especially in myeloid cell differentiation.
In this study, we have characterized the phenotype and activation pattern of subsets of dendritic
cells (DCs) in ICSBP
 
 
 
/
 
 
 
 mice. Remarkably, the recently identified mouse IFN-producing cells
(mIPCs) were absent in all lymphoid organs from ICSBP
 
 
 
/
 
 
 
 mice, as revealed by lack of
CD11c
 
low
 
B220
 
 
 
Ly6C
 
 
 
CD11b
 
 
 
 cells. In parallel, CD11c
 
 
 
 cells isolated from ICSBP
 
 
 
/
 
 
 
spleens were unable to produce type I IFNs in response to viral stimulation. ICSBP
 
 
 
/
 
 
 
 mice
also displayed a marked reduction of the DC subset expressing the CD8
 
 
 
 marker (CD8
 
 
 
 
 
DCs) in spleen, lymph nodes, and thymus. Moreover, ICSBP
 
 
 
/
 
 
 
 CD8
 
 
 
 
 
 DCs exhibited a
markedly impaired phenotype when compared with WT DCs. They expressed very low levels
of costimulatory molecules (intercellular adhesion molecule [ICAM]-1, CD40, CD80, CD86)
and of the T cell area-homing chemokine receptor CCR7, whereas they showed higher levels
of CCR2 and CCR6, as revealed by reverse transcription PCR. In addition, these cells were
unable to undergo full phenotypic activation upon in vitro culture in presence of maturation
stimuli such as lipopolysaccharide or poly (I:C), which paralleled with lack of Toll-like recep-
tor (TLR)3 mRNA expression. Finally, cytokine expression pattern was also altered in
ICSBP
 
 
 
/
 
 
 
 DCs, as they did not express interleukin (IL)-12p40 or IL-15, but they displayed de-
tectable IL-4 mRNA levels. On the whole, these results indicate that ICSBP is a crucial factor
in the regulation of two possibly linked processes: (a) the development and activity of mIPCs,
whose lack in ICSBP
 
 
 
/
 
 
 
 mice may explain their high susceptibility to virus infections; (b) the
generation and activation of CD8
 
 
 
 
 
 DCs, whose impairment in ICSBP
 
 
 
/
 
 
 
 mice can be re-
sponsible for the defective generation of a Th1 type of immune response.
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Introduction
 
IFN consensus sequence-binding protein (ICSBP)
 
*
 
 is a
component of the IFN regulatory factor (IRF) transcrip-
tion factor family, acting as an important regulator of
IFN-inducible genes (1). ICSBP binds with other mem-
bers of the IRF family and with the hematopoietic-spe-
cific member of the Ets family PU.1 to form transcrip-
tional complexes apparently critical for the regulation of
the immune system (2). The expression of ICSBP is re-
stricted to myeloid and lymphoid cell lineages, including
cells of monocyte/macrophage lineage, B lymphocytes,
and activated T lymphocytes (3). Some reports have pro-
vided evidence indicating that ICSBP plays a critical role
in modulating the immune response by influencing the
 
differentiation and maturation of immune cells and by
affecting cytokine expression (3, 4). Much of our knowl-
edge on the in vivo role of ICSBP has stemmed from
studies in mice lacking the expression of this transcription
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 DC, dendritic cell; ICAM, intercellular
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IPC, IFN-producing cell; NDV, Newcastle disease virus; PRR, pattern-
recognition receptor; TLR, Toll-like receptor. 
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factor. Of interest, knockout (ICSBP
 
 
 
/
 
 
 
) mice were
found to be highly susceptible to infection with various
pathogens including vaccinia virus and LCMV, bacteria as
 
Listeria monocytogenes
 
 and 
 
Yersinia enterocolitica
 
, and parasites
such as 
 
Leishmania major
 
 and 
 
Toxoplasma gondii
 
, whose ef-
fective host control is associated with a Th1 immune re-
sponse in normal mice (3, 5). Of note, several studies in-
dicate that ICSBP has a role in regulating pathways
affecting lineage commitment and myeloid cell differenti-
ation (2, 6). In this regard, ICSBP
 
 
 
/
 
 
 
 mice are character-
ized by altered hematopoiesis and develop a myelopro-
liferative disease resembling to chronic myelogenous
leukemia (CML) in humans (7). The development and
the response to cytokines of myeloid progenitors were
also found to be altered in these mice (2, 4). Moreover,
myeloid cells from ICSBP
 
 
 
/
 
 
 
 mice have been reported to
exhibit defective apoptosis, indicating that ICSBP plays a
role in the control of cell growth and differentiation of
myeloid cells at different developmental stages (8). Re-
cently, it has been reported that ICSBP can affect the pro-
liferative potential of myeloid cells at the progenitor cell
level, playing a role in promoting macrophage differentia-
tion, thus inhibiting the development of granulocytes (9).
In the present study, we have studied the role of ICSBP in
dendritic cell (DC) development and maturation by char-
acterizing different DC subsets in ICSBP
 
 
 
/
 
 
 
 mice as com-
pared with control animals.
DCs are the most powerful APCs, playing a key role in
triggering the immune system against infectious agents and
cancer. In tuning the immune response of the host to
pathogens, DCs undergo several stages of maturation by
differentiating from immature DCs, specialized in the cap-
ture of antigens at the various portals of microbe entry, to
mature APCs, with potent ability to prime naive helper
and cytotoxic T cells in secondary lymphoid organs (10).
DC maturation can be triggered by products of bacterial
or viral pathogens, through direct interaction with pattern-
recognition receptors (PRRs), such as Toll-like receptors
(TLRs) (11). Alternatively, DCs can be indirectly activated
by cytokines produced by infected cells (12). One impor-
tant family of infection-induced cytokines are type I IFNs
(IFN-
 
 
 
/
 
 
 
). IFN-
 
 
 
/
 
 
 
 not only represent one of the most
important line of innate defense against pathogens, but also
possess a variety of immunomodulatory activities (13–15),
including promoting effects on the differentiation/activa-
tion of DCs (16, 17).
Several subpopulations of DCs have been described both
in humans and in mice, based on phenotype, functional
potential and microenvironmental localization, which are
capable of inducing distinct types of responses (18, 19). Re-
cently, a rare DC subset with plasmacytoid characteristics
has been identified as the major IFN-producing cells (IPCs)
first in humans (20, 21) and subsequently in mice (22–24).
These cells represent a crucial cell type in the regulation of
the immune response, as upon interaction with various
types of pathogens, they trigger the innate immunity by
producing large amounts of IFN-
 
 
 
/
 
 
 
, which may subse-
quently initiate the adaptive immune response by promot-
ing differentiation of DCs and a Th1 type of immune response
(25, 26). Mouse IPCs express markers associated with lym-
phoid lineage, but lack expression of myeloid markers and ex-
press low levels of the DC marker CD11c (23, 24).
In mice, mature CD11c
 
 
 
 DCs can be classified in two
major DC subsets, on the basis of the expression of CD8, as
an 
 
  
 
 homodimer (27, 28). These CD8
 
 
 
 
 
 and CD8
 
 
 
 
 
DCs require different cytokines for their development (29)
and exhibit distinct biological functions, such as the ability
to induce Th1 and Th2 responses, respectively (30). Fur-
thermore, they display different anatomical distribution in
lymphoid organs, as CD8
 
 
 
 
 
 DCs are located in the T cell
areas, while CD8
 
 
 
 
 
 DCs reside in the marginal zone (31).
Whether this heterogeneity reflects the existence of distinct
lineages of DCs or different maturation stages, or both, re-
mains controversial.
In this study, we found that IPCs are almost undetect-
able in ICSBP
 
 
 
/
 
 
 
 mice and that this profound defect is as-
sociated with a marked impairment in the numbers and
activation properties of CD8
 
 
 
 
 
 DCs in all secondary lym-
phoid organs. These results unravel a previously unrecog-
nized important role of ICSBP in the regulation of the de-
velopment and activation of DCs.
 
Materials and Methods
 
Mice.
 
ICSBP-deficient mice were generated as described (7).
Homozygous deficient (
 
 
 
/
 
 
 
) and WT mice (
 
 
 
/
 
 
 
) on a
(C57BL/6 
 
 
 
 129/Sv) F
 
2
 
 background were bred and maintained
under specific pathogen-free conditions.
 
DC Isolation and Culture.
 
DCs were isolated from lymphoid
organs using a method similar to that described by Vremec et al.
(27). In brief, spleens, thymuses, mesenteric and skin-draining
(mandibular, axillary, inguinal, and popliteal) lymph nodes from
3–5 mice were pooled and cut into small fragments. Fragments
were digested in RPMI 1640 (Bio-Whittaker) containing 10%
FCS (SEBAM), 1 mg/ml type III collagenase (Worthington
Biochemicals), and 325 K units/ml DNase I (Sigma-Aldrich),
with periodic pipetting to break up fragments, for 25 min at
room temperature. EDTA (0.1 M, pH 7.2; Sigma-Aldrich) was
added for an additional 5 min, to allow disruption of DC–T cell
complexes. Cells were washed, resuspended in Nycodenz (1.077
g/ml; Life Technologies), overlaid on an additional layer of Ny-
codenz, and centrifuged at 1,700 
 
g
 
 for 20 min. The low-density
fraction was collected, washed, and either directly used for phe-
notypic analysis, or further incubated on ice with anti–CD11c-
FITC (Becton Dickinson) followed by anti–FITC-Microbeads
(Miltenyi Biotech). The positive fraction was recovered using a
MACS separation column and checked on a FACSort™ (Becton
Dickinson) for purity. The cells obtained were routinely 
 
 
 
95%
CD11c
 
 
 
. In some experiments, DCs were overnight cultured in
IMDM medium (Bio-Whittaker) supplemented with 10% heat-
inactivated FCS, 100 U/ml penicillin, 100 
 
 
 
g/ml streptomycin
(both from Bio-Whittaker), with or without added LPS, 0.5 
 
 
 
g/
ml, or poly (I:C), 100 
 
 
 
g/ml (all from Sigma-Aldrich).
 
mAbs and Flow Cytometry.
 
The following mAbs (all from BD
PharMingen) were used: anti-CD8a (53–6.7) either PE- or
FITC-labeled, anti–CD11b-PE (M1/70), anti-CD45R/B220
FITC (RA3–6B2), anti–CD54-biotin (3E2), anti–CD40-biotin
(HM40–3), anti–CD80-biotin (16–10A1), anti–CD86-biotin (GL1), 
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anti–H2D
 
b
 
-biotin (28–14–8), anti–I-A
 
d
 
/I-E
 
d
 
-biotin (2G9), anti–
Ly6C-biotin (AL-21), anti–CD45RB-biotin (16A), and anti-CD11c
(HL3), which was used in either PE-, FITC-, or biotin-conjugated
form. Biotinylated mAbs were detected with streptavidin-Red670
(Life Technologies). Stained cells were analyzed on a FACSort™
flow cytometer (Becton Dickinson). Viable cells were selected for
analysis based on forward- and side-scatter properties.
 
RT-PCR and Analysis of Amplified Products.
 
Total RNA was
extracted from 0.5–2 
 
 
 
 10
 
6
 
 magnetically-purified CD11c
 
 
 
splenic DCs by using the miniprep total RNA purification kit
(QIAGEN). 500 ng of RNA was incubated at 25
 
 
 
C for 10 min
with Oligo-p(dT)
 
15
 
 (Boehringer) in the presence of 50U RNase
inhibitors (Boehringer) and reverse-transcribed using 20 U of
AMV reverse transcriptase (Boehringer) for 1 h at 42
 
 
 
C in a final
volume of 20 
 
 
 
l (10 mM Tris, 50 mM KCl, 5 mM MgCl
 
2
 
, 1
mM dNTPs; pH 8.3). PCR was performed on 2 
 
 
 
l of each
cDNA sample using 1.25 U of Thermoprime Plus DNA poly-
merase (Advanced Biotechnologies) in a final volume of 50 
 
 
 
l
containing 75 mM Tris, 20 mM Ammonium Persulphate, 0.1%
Tween 20, 1.5 mM MgCl
 
2
 
, 0.2 mM dNTPs, 10 pmol of sense
primer, and 10 pmol of antisense primer at pH 8.8. The specific
primer pairs used were as follows: TLR3: 5
 
 
 
-TCGGATTCTTG-
GTTTCAAGG-3
 
 
 
 (sense) and 5
 
 
 
-CTTGCTGAACTGCGTGAT
GT-3
 
 
 
 (antisense); TLR4: 5
 
 
 
-AGTGGGTCAAGGAACAGA
AGCA-3
 
 
 
 (sense) and 5
 
 
 
-CTTTACCAGCTCATTTCTCACC-3
 
 
 
(antisense); CCR2: 5
 
 
 
-GGGCTCACTATGCTGCAAAT-3
 
 
 
 (sense)
and 5
 
 
 
-CGAAACAGGGTGTGGAGAAT-3
 
 
 
 (antisense); CC R6:
5
 
 
 
-ACTCTTTGTCCTCACCCTACCG-3
 
 
 
 (sense) and 5
 
 
 
-AT
CCTGCAGCTCGTATTTCTTG-3
 
 
 
 (antisense); CCR7: 5
 
 
 
-AC
AGCGGCCTCCAGAAGAACAGCGG-3
 
 
 
 (sense) and 5
 
 
 
-TGAC
GTCATAGGCAATGTTGAGCTG-3
 
  (antisense); IL-4: 5 -AT
GGGTCTCAACCCCCAGCTA-3  (sense) and 5 -CGAGTAAT
CCATTTGCATGAT-3  (antisense); IL-12p40: 5 -AACTGGCG
TTGGAAGCACGG-3  (sense) and 5 -GAACACATGCCCACT
TGCTG-3  (antisense); IL-15: 5 -CATATGGAATCCAACTGGA
TAGATGTAAGATA-3  (sense) and 5 -CATATGCTCGAGGGA
CGTGTTGATGAACAT-3  (antisense);  -actin: 5 -TGACGGG
GTCACCCACACTGTGCCCATCTA-3  (sense) and 5 -CTAG
AAGCATTGCGGTGGAGCATGGAGGG-3  (antisense). All pri-
mers were obtained from Invitrogen. The samples were amplified
for 30–40 cycles at different annealing temperatures, optimal to
each primer combination Tm. Amplified products (10  l) were
separated by agarose gel electrophoresis on a 1.2% TAE gel and
visualized by ethidium bromide staining and UV transillumina-
tion.  -actin RT-PCR was run in parallel to normalize the levels
of mRNA in the samples. The relative density of amplified bands
was determined by LKB XL Ultroscan densitometer (Amersham
Biosciences).
In Vitro Stimulation of DCs and IFN Bioassay. 3    105 mag-
netically sorted splenic DCs ( 97% CD11c ) were infected with
Newcastle disease virus (NDV; 576 UE/ml) for 1 h at 37 C, 5%
CO2, then washed and cultured in 300  l/well of a 48 well-plate for
18 h, after which the supernatant was harvested. 50  l of each sample
was assayed for IFN- /  biological activity by measuring its ability to
confer resistance to vesicular stomatitis virus (VSV) infection upon
L929 cells as described elsewhere (32). Each IFN unit, as expressed in
the text, represents 4 IU.
Results
ICSBP /  Mice Lack mIPCs and Show Impaired IFN- / 
Production during Viral Infection. Murine IPCs display a plasma-
cytoid morphology and have been phenotypically character-
ized as CD11clowCD11b B220 Ly6C CD 45 RB MHC-IIlow
(22–24). To identify mIPCs in ICSBP /  and WT mice,
DC-enriched cell populations were obtained from spleen,
thymus, skin-draining and mesenteric lymph nodes by Ny-
codenz density-gradient centrifugation and the low-density
fraction was subsequently stained with a panel of monoclo-
nal antibodies. The staining for CD11c marker allowed us
to gate on a population expressing this molecule at high
and low levels, as indicated in Fig. 1 A. DCs were further
stained for CD11b and Ly6C, as the expression of these
surface markers allowed to identify mIPCs, which have
been characterized as CD11clowCD11b Ly6C  cells (23,
24). As shown in Fig. 1 B, the flow cytometric analysis re-
vealed a well-defined CD11b Ly6C  DC population (gate
R3) in all organs from control mice. Strikingly, ICSBP / 
mice lacked these cells in all tissues. To confirm these re-
sults, we stained the cells with anti-CD11b coupled with
anti-CD45RB, and analyzed the number of mIPCs, as
CD11b CD45RB  in the CD11c  gate (23). As shown in
Fig. 1 C, a region of CD11b CD45RB  cells (gate R4)
could be identified in control mice, while these cells were
almost undetectable in all organs from ICSBP /  mice.
To better characterize the surface phenotype of mIPCs,
splenic plasmacytoid cells were further analyzed by using
three-color analysis for the expression of CD11c, CD11b,
and alternately B220, MHC-II, CD40, Ly6C, and
CD45RB. As shown in Fig. 1 D, CD11clowCD11b  cells
from control mice (gate R2) were found positive for B220
and CD45RB, expressed low levels of MHC-II and con-
siderable levels of Ly6C, but were negative for the activa-
tion marker CD40, in accordance to what has been re-
cently reported by Asselin-Paturel et al. (23). In contrast,
the mIPCs (gate R2) were almost undetectable in spleens
from ICSBP /  mice, as revealed by the absence of stain-
ing for B220, MHC-II, CD40, and Ly6C markers.
To check whether the absence of mIPCs in lymphoid
tissues of ICSBP /  mice was indeed associated with a de-
fective production of IFN- /  upon virus stimulation, we
purified DCs from spleens of ICSBP /  or WT mice and
infected them with NDV. The IFN- /  production was
then determined in the culture supernatants by biological
assay. As expected, NDV infection did not induce signifi-
cant release of IFN- /  in DCs from ICSBP /  mice,
whereas large amounts of this cytokine were found in con-
trol-DC cultures (Fig. 2).
ICSBP /  Mice Exhibit Severe Reductions in and Altered
Phenotype of CD8   DCs. Two major DC subsets have
been identified in the mouse lymphoid organs on the basis
of their differential CD8  expression, named CD8   and
CD8   DCs (27). Additional reports have further indi-
cated that the CD8   DCs can be in turn distinguished on
the basis of CD4 expression (33). This complex heteroge-
neity could reflect a different state of activation, matura-
tion, mobilization (34–36), or divergent ontogeny of DCs
(37).
We therefore examined the distribution of CD8   and
CD8   DC subsets in spleens, thymus, mesenteric and
skin-draining lymph nodes from ICSBP /  or WT mice.1418 Dendritic Cell Development and Interferon Consensus Sequence-binding Protein
Figure 1. ICSBP /  mice lack IPCs in all lymphoid organs. DCs were isolated from spleen, thymus, skin-draining and mesenteric lymph nodes from
ICSBP /  or WT mice. Nycodenz-enriched DCs were triple-stained for CD11c, CD11b, and alternatively for Ly6C, CD45RB, CD40, I-A, or B220
markers and then analyzed by flow cytometry for detection of mouse IPCs. (A) A region (R2 gate) was drawn on DC populations expressing CD11c at
both low and high levels. (B and C) R2-gated DCs from the indicated lymphoid organs were analyzed for the expression of CD11b and Ly6C (B), or
CD45RB (C). Regions (R3 and R4) identify IPCs (see text). (D) Surface phenotype of IPCs in spleens from ICSBP /  and WT mice. Filled histograms
show specific staining for the indicated markers in the CD11b CD11clow cell population (R2 gate). Open lines represent isotype-matched control. Data
are representative of one experiment of three.1419 Schiavoni et al.
Gradient-enriched DCs were double-stained for CD11c
and CD8  markers and analyzed by flow cytometry. As il-
lustrated in Fig. 3 A, showing the expression of CD8  in
spleen DCs gated by CD11c positivity and forward side
scatter properties, 32% of splenic DCs were CD8   in WT
mice, similarly to values previously found in other mouse
strains (19). Surprisingly, spleen CD8   detected in
ICSBP /  mice only represented 3.6% of the total DC
population. To further analyze the maturation and activa-
tion phenotype of CD8   and CD8   subsets of splenic
DCs from ICSBP /  and control mice, we performed
three-color flow cytometric analysis combining the CD11c
and CD8  markers alternatively with the costimulatory an-
tigens CD40, CD80, CD86, intercellular adhesion mole-
cule (ICAM)-1, and the MHC class I and class II mole-
cules. As shown in Fig. 3 B, the CD8   DC subpopulation
from ICSBP /  mice expressed significantly lower levels of
the costimulatory antigens CD40, CD80, CD86, and
ICAM-1 with respect to the WT counterparts. In contrast,
Figure 2. Defective production of IFN- /  in DCs from ICSBP / 
mice after in vitro infection with NDV. Magnetically-purified DCs
( 97% CD11c ), obtained from spleens of ICSBP /  and WT mice,
were infected with NDV for 1 h. Virus was then washed out, and cells
were incubated for 18 h, at 37 C. The supernatant was harvested and
assayed for IFN- /  bioactivity, as described in Materials and Methods.
Data are representative of two independent experiments.
Figure 3. Impaired number and phenotype of CD8   DCs in spleens from ICSBP /  mice. Spleens from ICSBP /  or WT mice were pooled and
enriched for DCs by Nycodenz density-gradient centrifugation, as described in Materials and Methods. (A) The low-density cell fraction was double-
stained for CD11c and CD8  expression. The histograms show the percentage of CD8   DCs in ICSBP /  and WT mice, gated for CD11c positivity
and by forward side scatter properties. (B) The CD8   and CD8   CD11c  DC-subsets were additionally stained for ICAM-1, CD40, CD80, CD86,
MHC class I, or class II molecules. Histograms show specific staining for the indicated antigens in CD8   CD11c  (left) and CD8 - CD11c  (right)
gated populations, in ICSBP /  (filled) and WT (open) mice. The broken profiles represent the background fluorescence for control isotype-matched
antibodies. (C) Forward scatter profiles of CD8   (filled histograms) and CD8   (open histograms) CD11c  DCs from ICSBP /  and WT mice. (D)
Density plot analysis showing CD4 and CD8  expression in CD11c-gated DCs from ICSBP /  and WT mice. Results are representative of at least five
independent experiments.1420 Dendritic Cell Development and Interferon Consensus Sequence-binding Protein
in the CD8   DC-subset all the considered costimulatory
antigens and activation markers were expressed at compara-
ble levels in ICSBP /  and WT mice. The altered pheno-
type of CD8   DCs in ICSBP /  mice was further con-
firmed by the morphologic analysis of the forward scatter
profile (Fig. 3 C), showing that, consistently with previous
reports (36), splenic CD8   DCs were bigger than
CD8   DCs in WT mice. Conversely, CD8   DCs re-
covered from the spleens of ICSBP /  mice proved to be
significantly smaller than CD8   DCs.
CD8   DCs can also express the CD4 marker and
CD4 CD8   and CD4 CD8   DCs have been described to
be present in the mouse spleen in a 3:1 ratio (19). To deter-
mine whether the CD4 molecule was differentially expressed
in CD8   splenic DCs from ICSBP /  mice, we performed
immunofluorescent staining of gradient-enriched CD11c 
DCs for CD4 and CD8  expression. As shown in Fig. 3 D,
the percentage of CD4  DCs was significantly higher in
ICSBP /  than in control mice. In fact, the representation of
the CD4 CD8   versus CD4 CD8   DC subsets was in
a 5:1 ratio in knockout mice, which contrasts with the 2.5:1
ratio found in WT animals.
The analysis of the other lymphoid organs, where the
frequencies of CD8   DCs are generally more consistent,
revealed that this DC subset was markedly reduced in all of
them in ICSBP /  mice (Fig. 4 A). Moreover, three-color
analysis showed that the expression of ICAM-1, CD40,
CD80, and CD86 in the CD8   DC-subset from skin-
draining and mesenteric lymph nodes was also impaired
(Fig. 4 B). In fact, CD8   DCs from control mice could
be clearly separated in two populations, one expressing in-
termediate to high levels of each activation marker (gate
R3), and one showing low or no expression of these mole-
cules (gate R4). Remarkably, the highly activated CD8  
DC population (gate R3) was barely detectable in lymph
nodes from ICSBP /  mice, as indicated by the absence of
ICAM-1hi, CD40 , and CD86  cells, even though consid-
erable levels of CD80 expression were retained. Overall,
these results indicate that ICSBP is essential for the devel-
opment and maturation of mouse CD8   DCs.
Altered Response of CD8   DCs from ICSBP /  Mice to
Activation Signals.  Because DCs are extremely tuned to
respond to activation stimuli, even manipulation and
short-time culture has been described to activate DCs (38,
39). We therefore wanted to address whether the unbal-
ance of CD8   and CD8   DC subsets might affect the
ability of ICSBP /  DCs to undergo phenotypic matura-
tion upon in vitro culture. To this end, CD11c  DCs
were magnetically sorted from spleens of ICSBP /  and
WT mice, cultured for 18 h and then stained for surface
markers expression. Fig. 5 A shows the mean fluore-
scence intensity values of the indicated markers in CD8  
-gated and CD8  -gated populations. CD8   DCs from
ICSBP /  mice exhibited a clear-cut reduction in the ex-
pression of the costimulatory molecules CD40, CD80, and
CD86, the adhesion antigen ICAM-1 and the activation
markers MHC class I and class II, as compared with the
control counterparts. In contrast, CD8   DCs from
ICSBP /  and WT mice exhibited similar levels of CD40,
CD80, CD86, and ICAM-1. Interestingly, the expression
of MHC class I and class II was significantly lower in
ICSBP /  CD8   DCs, indicating that optimal activation
was compromised also in this subset.
Next, we examined whether in vitro treatment with dif-
ferent maturation stimuli, such as LPS or poly (I:C) could
activate DCs from ICSBP /  mice. As shown in Fig. 5 B,
addition of LPS or poly (I:C) to the DC cultures, increased
the expression of the costimulatory markers CD40, CD80,
and CD86 in DCs from both genotypes. Nevertheless, the
intensity of expression of these molecules was significantly
lower in CD8   DCs from ICSBP /  mice, indicating
that full activation did not occur in ICSBP /  DCs. To as-
sess whether the defective responsiveness of ICSBP / 
DCs to these two stimuli was due to altered expression of
PRRs, we analyzed the expression of TLR4 and TLR3,
which are known to recognize LPS (40) and poly (I:C; ref-
erence 41), respectively. Fig. 5 C shows TLR3 and TLR4
mRNA expression, as revealed by RT-PCR, in freshly iso-
lated, magnetically sorted splenic DCs from ICSBP /  and
WT mice. Interestingly, ICSBP /  DCs did not express
detectable TLR3 mRNA, whereas they expressed higher
levels of TLR4 mRNA than control DCs.
Chemokine Receptor and Cytokine Expression in DCs from
ICSBP /  Mice Reflects the Prevalence of CD8   Subsets.
The differential expression of chemokine receptors identi-
fies distinct DC maturation stages and ensures a correct
trafficking of these cells to lymphoid organs (42). We then
performed RT-PCR for the detection of chemokine re-
ceptors implicated in the anatomical localization and matu-
ration stage of CD8   and CD8   DC subsets in lym-
phoid tissues (43). Notably, freshly isolated splenic DCs
from ICSBP /  mice expressed significantly higher levels
of CCR2 (twofold) and CCR6 (threefold) as compared
with the WT counterparts, while they showed lower levels
(2.5-fold) of CCR7, whose expression is associated with
maturating DCs (44; Fig. 6 A).
Although CD8   and CD8   DC subsets appear to be
equally competent at presenting antigen to T cells in vivo,
they are known to possess distinct cytokine profiles, which,
under certain experimental conditions, can drive either the
Th1 or Th2 response (45, 46). Therefore, the imbalance
between CD8   and CD8   DC subsets in ICSBP / 
mice, could result in altered expression of cytokines, which
might in turn affect some DC functions. To evaluate the
expression pattern of cytokines, RNA was extracted from
freshly-isolated magnetically sorted CD11c  DCs from
ICSBP /  or WT mice, and IL-12p40, IL-15, or IL-4
mRNA expression was evaluated by RT-PCR. As illus-
trated in Fig. 6 B, ICSBP /  DCs did not express any de-
tectable level of IL-12p40 and showed very low levels of
IL-15, but they displayed some IL-4 mRNA expression. In
contrast, DCs from WT mice showed a clear-cut expres-
sion of both IL-12p40 and IL-15 mRNA, while they did
not apparently express IL-4 mRNA.1421 Schiavoni et al.
Discussion
This study provides the first evidence that ICSBP, a
transcriptional factor acting in the IFN signaling, plays a
key role in the development of mIPCs and in the genera-
tion and activation of CD8   DCs. The most striking ob-
servation reported in this paper is the lack of mIPCs in
ICSBP /  mice. This recently identified cell subset, which
is responsible for the production of large amounts of type I
IFN after virus infection, is characterized by a plasmacytoid
Figure 4. Highly reduced per-
centage of CD8   DCs in all
lymphoid organs from ICSBP / 
mice. Density gradient-enriched
DCs were obtained from thy-
mus, skin-draining and mesen-
teric lymph nodes of ICSBP / 
or WT mice. (A) DC prepara-
tions were double stained for
CD11c and CD8  expression
and then analyzed by flow cy-
tometry. Filled histograms show
CD8  expression in CD11c-
gated populations of the indi-
cated organs. Open lines repre-
sent isotype-matched controls.
(B) Dot plot analysis of CD8  
and CD8  , CD11c-gated DCs,
alternatively labeled with anti–
ICAM-1, CD40, CD80, or
CD86 specific antibodies. Re-
gions were drawn (R3 and R4)
to identify CD8   subpopula-
tions expressing the indicated
molecules at different levels, in
lymph nodes from ICSBP /  or
WT mice. Representative data
of one experiment out of four
are shown.1422 Dendritic Cell Development and Interferon Consensus Sequence-binding Protein
morphology and by the expression of specific markers. In
particular, mouse IPCs exhibit low levels of the DC marker
CD11c, lack of the myeloid marker CD11b and are character-
ized by the coexpression of the neutrophil marker Ly6C and the
B cell marker B220 (22–24). Moreover, these cells express sig-
nificant levels of CD45RB and MHC class II, but lack of CD40
marker (23, 24). The lack of IPCs in ICSBP /  mice was re-
vealed not only by the absence of a defined population of
CD11clowCD11b Ly6C B220 CD45RB MHC-II CD40 
cells in spleen, thymus, skin-draining and mesenteric lymph
nodes, but also by the marked defect in the production of
type I IFN by DC cultures from these mice. The lack
of IFN- /  production may explain the susceptibility of
ICSBP-deficient mice to some viral infections such as vac-
cinia virus (VV; reference 7). Of note, even though
ICSBP /  mice can control VSV infection, they develop
an impaired CTL response to this virus, which has been re-
ported to activate IPC localized in the marginal zone (47).
Figure 5. Reduced activation
of CD8   splenic DCs from
ICSBP /  mice, after short-time
culture. CD11c  DCs were pu-
rified from spleens by magnetic
cell-sorting (see Materials and
Methods). Cells obtained from
both ICSBP /  and WT mice
were cultured in complete me-
dium for 24 h, at 37 C. (A)
Overnight-cultured DCs were
stained for CD8  and alterna-
tively for ICAM-1, CD40,
CD80, CD86, or the molecules
MHC class I and class II. The
mean fluorescence distributions
for the indicated antigens in
CD8   and CD8   subsets are
represented by black bars for
DCs isolated from ICSBP / 
mice or white bars for DCs from
WT mice. (B) CD8   DCs
from cultures, treated or not
with LPS or poly (I:C), were
stained for the costimulatory
molecules CD40, CD80, or
CD86. The staining for the indi-
cated antigens is represented by
filled histograms for CD8  
DCs from ICSBP /  mice and
open histograms for CD8   DC
from WT mice. The broken
profiles show isotype-matched
controls. (C) Total RNA was
extracted from freshly isolated
magnetically sorted CD11c 
splenic DCs from ICSBP /  and
control mice. TLR3 and TLR4
mRNA levels were detected by
RT-PCR. Representative data
of one experiment out of four
are shown.
Figure 6. Expression of cytokines and chemokine receptors in DCs
from ICSBP /  mice. DCs were isolated from pooled spleens from
ICSBP /  or WT mice. CD11c  DCs were magnetically sorted, as indi-
cated in Fig. 5. Total RNA was extracted from freshly isolated DC prep-
arations and assayed for the expression of the indicated chemokine recep-
tors (A) or cytokines (B) by RT-PCR. Representative data of one
experiment out of three are shown.1423 Schiavoni et al.
Taken together, our data suggest a key role of this transcrip-
tion factor in the development of mIPC lineage with conse-
quent profound deficits in immune functions. Although the
precise stage of the mIPC developmental program controlled
by ICSBP remain to be clarified, we favor the hypothesis
that the activity of this transcriptional factor becomes a criti-
cal determinant in an IPC-committed precursor, as ICSBP / 
mice are still competent at producing other DC subsets.
Another important finding reported in this study is the
marked impairment in the number and activation stage of
CD8   DCs observed in various tissues from ICSBP / 
mice. CD8   and CD8   DCs were originally reported as
distinct lineages, lymphoid- and myeloid-derived, respec-
tively, endowed with distinct cytokine requirements and
development regulation mechanisms (48), as mice deficient
for RelB, a transcription factor of the nuclear factor (NF)-
kB family, normally generate CD8   DCs but lack of
CD8   DC subtype (49). However, recent studies have
challenged this concept by demonstrating that both
CD8   and CD8   DCs can be generated from either
lymphoid or myeloid progenitors (50) and a common pre-
cursor population, yielding CD8   and CD8   as well as
B220  DCs, has been characterized (51). The marked im-
pairment in the levels of CD8   DCs in lymphoid tissues
from ICSBP /  mice and the poorly activated phenotype
of these cells reported in the present study might account
for the impaired Th1 response previously observed in these
mice (5, 52). In addition, CD8   DCs from ICSBP / 
mice displayed low levels of the surface markers CD40,
CD80, CD86 ICAM-1, and MHC class I and II along with
a significantly small size as evaluated by morphologic analy-
sis. Consistent with our data, Aliberti et al., (2002) have re-
cently reported that ICSBP is preferentially expressed by
the CD8   DC subset and that ICSBP /  mice display a
selective reduction of CD8  DEC205  DCs, which is as-
cribed to an intrinsic defect of bone marrow–derived pro-
genitors (53). Of interest, we also found that, even though
the absence of ICSBP did not affect the expression of co-
stimulatory molecules in CD8   DCs, it influenced the
frequencies of CD4  and CD4 . At present, the lineage re-
lationship between CD4  and CD4  DCs relative to the
CD8   subtype is unknown (54); however, as these sub-
types could reflect different maturation stages (33), the
prevalence of CD4 CD8   DCs in ICSBP /  mice is
likely to be correlated to a specific role of this factor in
controlling DC maturation. The concept that ICSBP can
play a role in DC maturation is also supported by our find-
ings that ICSBP /  DCs expressed high levels of CCR6
and CCR2, receptors both present on immature DCs (55,
56), as well as low levels of CCR7, whose expression is up-
regulated in mature DCs, driving their migration into T
cell areas of secondary lymphoid organs (44). The control
by ICSBP on maturation of CD8   DCs, and to a lower
extent of CD8   DCs, was also evident upon activation by
LPS or poly (I:C) treatment (57), as these agents failed to
induce full phenotypic activation in DCs from ICSBP / 
mice. Notably, the unresponsiveness of ICSBP /  DCs to
poly (I:C) correlated with lack of expression of TLR3,
which has been recently reported to recognize dsRNA
(41). In contrast, these cells were found to exhibit high lev-
els of TLR4, indicating that the inability of CD8   DCs to
be activated by LPS is likely due to an intrinsic defect,
rather than to a lack of this specific PRR. Notably,
ICSBP /  DCs showed a qualitative difference in cytokine
expression with respect to DCs from control mice, as IL-12
and IL-15 mRNAs were undetectable, while some expres-
sion of IL-4 was observed. This cytokine profile appears to
be consistent with the Th2 bias of ICSBP deficient mice
(5) as well as with the preferential presence of CD8   DCs
in lymphoid organs (58).
On the whole, our findings demonstrate that ICSBP is
essential for the development of mIPC and plays an impor-
tant role in the generation of CD8   DCs. This transcrip-
tion factor may also affect the terminal stages of CD8  
DC maturation. We suggest that the activity of ICSBP be-
comes relevant at different stages in the distinct DC lin-
eages. It may control the development of a mIPC-commit-
ted precursor and, in parallel, may delay the differentiation
program of a progenitor of CD8   DCs (51, 54). Alterna-
tively, if CD8   DCs and mIPC represent different matu-
ration stages of the same DC subpopulation, a question
raised by some authors (23, 58), we can argue that ICSBP
may act as a key factor in controlling the developmental
maturation program of these cells.
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